ANNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Annexon's EBIT per Share for the three months ended in Dec. 2023 was $-0.38. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.91.
During the past 3 years, the average EBIT per Share Growth Rate was 20.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Annexon's EBIT per Share or its related term are showing as below:
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Annexon was 20.20% per year. The lowest was -26.80% per year. And the median was -2.40% per year.
Annexon's EBIT for the three months ended in Dec. 2023 was $-30.01 Mil.
The historical data trend for Annexon's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EBIT per Share | Get a 7-Day Free Trial | -2.48 | -3.74 | -3.41 | -2.66 | -1.90 |
Annexon Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EBIT per Share | Get a 7-Day Free Trial | -0.51 | -0.56 | -0.50 | -0.46 | -0.38 |
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Annexon's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as
EBIT per Share | (A: Dec. 2023 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -143.723 | / | 75.673 |
= | -1.90 |
Annexon's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as
EBIT per Share | (Q: Dec. 2023 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -30.009 | / | 78.247 |
= | -0.38 |
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.91
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon (NAS:ANNX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Thank you for viewing the detailed overview of Annexon's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Ted Yednock | officer: EVP & Chief Innovation Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Muneer A Satter | director | C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
Jamie Dananberg | officer: Chief Medical Officer | 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jennifer Lew | officer: EVP & Chief Financial Officer | 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
Michael Overdorf | officer: EVP & Chief Business Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Bain Capital Life Sciences Fund, L.p. | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Douglas Love | director, officer: President & CEO | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Dean Richard Artis | officer: EVP & Chief Scientific Officer | C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005 |
Bettina M. Cockroft | director | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Larry Mattheakis | officer: Chief Scientific Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Sanjay Keswani | officer: EVP & Chief Medical Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
William H. Carson | director | C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016 |
Clarus Lifesciences Iii, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By Marketwired • 10-24-2023
By GlobeNewswire • 12-20-2023
By Value_Insider Value_Insider • 10-18-2022
By GlobeNewswire • 12-20-2023
By GlobeNewswire • 01-08-2024
By Marketwired • 07-27-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GlobeNewswire • 12-20-2023
By Value_Insider Value_Insider • 11-17-2022
By Marketwired • 08-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.